Uses of Mitotax

Mitotax belongs to the group of anti-cancer drugs and affects the immune system, with the main ingredient being Paclitaxel 6mg/ml. Paclitaxel belongs to the Taxane group and has the effect of inhibiting the growth of cancer cells, anti-cancer, and modulating the immune response to prolong the life of patients.
Mitotax is prepared in the form of an injection, packaged in a 5ml tube and is indicated for use in the following cases:
Treatment of metastatic ovarian cancer in case of failure with other measures or the patient is not able to point. Adjuvant treatment of metastatic breast cancer in combination with doxorubicin in case of failure of other measures or in patients with recurrence after 6 months of adjuvant therapy. Treatment of HIV/AIDS-associated non-small cell lung cancer and Kaposi's cancer.

2.1 How to use Mitotax Mitotax medicine is used by intravenous infusion, the infusion includes from drug preparation to injection technique conducted by experienced medical staff or doctors, ensuring safety bacteria and do not allow the drug to come into contact with mucous membranes or skin. In case of accidental skin contact, wash immediately with soap and water. If the medicine comes into contact with the mucous membranes, use clean water to clean it.
One of the following solvents can be used to dilute Mitotax before infusion:
0.9% sodium chloride solution 5% glucose solution Mixture of 0.9% sodium chloride solution and glucose solution 5 % Mixture of 5% glucose solution and ringer solution Mitotax medicine is usually made into an infusion solution with a concentration of 0.3 - 1.2mg/ml. The infusion must be stabilized at room temperature within 27 hours and within 3 hours of reconstitution, the infusion must be carried out immediately. Note, the reconstituted infusion should not be refrigerated.
2.2 Mitotax dosage Before infusion of Mitotax, the patient should be treated for hypersensitivity and anaphylaxis, which is life-threatening, specifically as follows:
Before infusion of Mitotax, the patient should take oral medication. Prednisolone with a dose of 30-40mg/time (corresponding to 6-8 tablets/time, 5mg/tablet), the first time 12 hours before infusion and the second time 6 hours before infusion. In combination with H1 receptor antagonist Clemastine, 30-60 minutes before infusion of Mitotax, intravenous infusion of Clemastine with a dose of 2mg and Cimetidine with a dose of 300mg or Ranitidine with a dose of 50mg. Before the course of treatment, oral or intravenous Dexamethasone with a dose of 20mg, the first time 12 hours before infusion and the second time 6 hours before infusion. From 30 to 60 minutes, intravenous injection of Cimetidine at a dose of 300mg or Ranitidine at a dose of 50mg and Diphenhydramine at a dose of 50mg. During treatment, Mitotax intravenous infusion at a dose of 135 - 175 mg/m2 body surface area, over 3 or 24 hours and treatment for 3 weeks. Do not repeat this dose when the white blood cell count is below 1,500/mm3 and the platelet count is less than 100,000/mm3.
Depending on the characteristics of the tumor (nature, volume), the patient's ability to respond and tolerance to chemotherapy, the dose of Mitotax is different. For the treatment of ovarian cancer are as follows:
First choice regimen in the treatment of advanced ovarian carcinoma in combination with cisplatin: There are 2 regimens, based on toxicity to choose the appropriate regimen. . Regimen 1 is an intravenous infusion of Mitotax at a dose of 175 mg/m2 over 3 hours, followed by an intravenous infusion of cisplatin at a dose of 75 mg/m2, each 3 weeks apart. Regimen 2 is an intravenous infusion of Mitotax at a dose of 135mg/m2 over 24 hours, followed by an intravenous infusion of cisplatin at a dose of 75mg/m2, each 3 weeks apart. Second-line regimen in the treatment of advanced ovarian cancer, or as a follow-up: Mitotax intravenous infusion at a dose of 135 or 175 mg/m2 over 3 hours, repeated after 3 weeks if the patient tolerates the drug. For breast cancer treatment:
Adjuvant treatment of breast cancer with lymph nodes: Intravenous infusion of Mitotax at a dose of 175mg/m2 for 3 hours, with 4 courses of treatment and 3 weeks apart. Second-line regimen in the treatment of advanced breast cancer: Intravenous infusion of Mitotax at a dose of 175 mg/m2 over 3 hours, each course of treatment 3 weeks apart. For the treatment of non-small cell lung cancer in combination with cisplatin (in patients who do not receive radiation therapy or have surgery indications), choose one of the following two regimens:
Regimen 1: Mitotax intravenous infusion at a dose of 135mg /m2 for 24 hours, followed by an intravenous infusion of cisplatin at a dose of 75mg/m2, 3 weeks apart. Regimen 2: Mitotax intravenous infusion at a dose of 175mg/m2 for 3 hours, followed by intravenous infusion of cisplatin at a dose of 80mg/m2, each course of treatment 3 weeks apart. For the treatment of HIV/AIDS-related Kaposi cancer as follows:
In advanced HIV patients: Mitotax should only be used when the neutrophil count is at least 1,000/mm3. In patients unresponsive to first-line regimens or subsequent chemotherapy: Regimen 1 is an intravenous infusion of Mitotax at a dose of 135 mg/m2 over 3 hours, 3 weeks apart. Regimen 2 is an intravenous infusion of Mitotax at a dose of 100mg/m2 over 3 hours, 2 weeks apart.

Mitotax medicine can cause some unwanted side effects such as: digestive disorders, increased liver enzymes, low blood pressure, bone marrow depression, musculoskeletal pain, hair loss, peripheral neuropathy.
Patients should be closely monitored during the use of Mitotax, if side effects occur, they should immediately notify the treating doctor for timely treatment.

Do not use Mitotax in people with hypersensitivity to the components of the drug; patients with neutrophil count less than 1,500/mm3; patients with obvious motor neuron disease symptoms; pregnant or lactating women; children under 18 years of age (effectiveness and safety have not been measured). Patients with impaired liver function, liver dysfunction should be adjusted to reduce the dose of Mitotax drug, especially patients with transaminase levels 10 times higher than normal or bilirubin levels above 7.5mg. /100ml (or 5 times higher than normal). People with heart disease, peripheral nerves (due to diabetes or chemotherapy) need to be careful when using Mitotax. Elderly people taking the drug are at a higher risk of toxic effects of the drug. Preventive treatment of hypersensitivity and always ready to take measures to treat anaphylaxis if it occurs, because in the excipients of Mitotax there is Cremophor EL. To reduce the risk of myelosuppression when multiple drugs or taxane derivatives are administered sequentially, platinum derivatives should be administered first. The use of Mitotax drug is to inhibit, prevent cancer cells from growing and prolong survival in patients with breast cancer, metastatic or recurrent ovarian cancer, non-small cell lung cancer and other diseases. HIV patient with Kaposi's cancer.
Follow Vinmec International General Hospital website to get more health, nutrition and beauty information to protect the health of yourself and your loved ones in your family.